MANKIND PHARMA
- Country
- 🇮🇳India
- Ownership
- -
- Established
- 1995-01-01
- Employees
- -
- Market Cap
- $11.5B
Clinical Trials
22
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma
- Conditions
- Glaucoma, Open-Angle
- Interventions
- Drug: Test - Bimatoprost 0.01% Ophthalmic SolutionDrug: Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Mankind Pharma Limited
- Target Recruit Count
- 310
- Registration Number
- NCT04890106
- Locations
- 🇺🇸
CBCC Global Research Site:011, Bakersfield, California, United States
🇺🇸CBCC Global Research Site 016, Mission Hills, California, United States
🇺🇸CBCC Global Research Site 017, Newport Beach, California, United States
News
Advent International Invests $175 Million in Animal Health Generics Company Felix Pharmaceuticals
Advent International has signed a definitive agreement to invest $175 million for a significant minority stake in Felix Pharmaceuticals, a Dublin-based company developing generic medicines for companion animals.
India's ₹5,000 Crore PRIP Scheme Signals Major Shift from Generic Manufacturing to Innovation-Led Pharma Growth
India launches the ₹5,000 crore Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme, expected to attract ₹17,000 crore in additional R&D investment by end of 2025.
Novartis Launches Zero-Interest Payment Plan for High-Cost Cholesterol Drug Inclisiran in India
Novartis has introduced a first-of-its-kind financing scheme with Pine Labs for its cholesterol-lowering drug Sybrava (inclisiran) in India, offering zero-interest EMI options to improve patient access.
NPPA Sets Retail Prices for 84 Drugs Including Empagliflozin Combinations Following Patent Expiry
India's National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 84 new drug formulations, including 36 combinations containing the recently off-patent diabetes medication empagliflozin.
CDSCO Panel Rejects Phase III Trial Waivers for Resmetirom in India, Approves Bioequivalence Studies
India's CDSCO expert committee has rejected Phase III clinical trial waivers for Resmetirom tablets proposed by both Morepen Laboratories and Mankind Pharma, requiring local clinical data before marketing approval.
Indian Pharma Companies to Launch Generic Empagliflozin at 90% Lower Cost
Several Indian pharmaceutical companies are preparing to launch generic versions of Empagliflozin following Boehringer Ingelheim's patent expiry on March 11, potentially transforming diabetes treatment accessibility.
Mankind Pharma Advances Novel Oral Anti-Obesity Drug in Phase 2 Trials
• Mankind Pharma has developed a pioneering GPR109 agonist as the world's first potential small-molecule oral treatment for obesity, currently advancing through Phase 2 trials in Australia. • The innovative drug offers advantages over existing injectable peptide treatments like Wegovy and Mounjaro, requiring no food-related restrictions and providing a more convenient oral administration route. • Phase 1 results have shown promising outcomes, with Phase 2 trial results expected by the end of the year, positioning Mankind Pharma for a potential breakthrough in the global obesity treatment market.